Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accounts Payables (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Accounts Payables data on record, last reported at $16.6 million in Q4 2025.

  • For Q4 2025, Accounts Payables rose 42.61% year-over-year to $16.6 million; the TTM value through Dec 2025 reached $16.6 million, up 42.61%, while the annual FY2025 figure was $16.6 million, 42.61% up from the prior year.
  • Accounts Payables reached $16.6 million in Q4 2025 per SNDX's latest filing, up from $13.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $17.4 million in Q2 2025 and bottomed at $3.6 million in Q2 2021.
  • Average Accounts Payables over 5 years is $8.8 million, with a median of $8.1 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: decreased 27.44% in 2021, then soared 182.28% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $5.7 million in 2021, then decreased by 23.27% to $4.4 million in 2022, then soared by 128.99% to $10.0 million in 2023, then increased by 16.72% to $11.6 million in 2024, then surged by 42.61% to $16.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $16.6 million in Q4 2025, $13.8 million in Q3 2025, and $17.4 million in Q2 2025.